科研製薬の株価時系列
日付 | 始値 | 高値 | 安値 | 終値 | 前日比 | 騰落率 | 出来高 |
---|---|---|---|---|---|---|---|
2022/01/25 | 4,215 | 4,260 | 4,195 | 4,225 | -50 | -1.2% | 66,300 |
2022/01/24 | 4,180 | 4,280 | 4,180 | 4,275 | +40 | +0.9% | 75,800 |
2022/01/21 | 4,215 | 4,235 | 4,175 | 4,235 | +25 | +0.6% | 71,300 |
2022/01/20 | 4,230 | 4,275 | 4,195 | 4,210 | -15 | -0.4% | 92,700 |
2022/01/19 | 4,220 | 4,260 | 4,210 | 4,225 | -35 | -0.8% | 87,100 |
2022/01/18 | 4,330 | 4,335 | 4,245 | 4,260 | -40 | -0.9% | 58,300 |
2022/01/17 | 4,295 | 4,345 | 4,270 | 4,300 | -20 | -0.5% | 50,000 |
2022/01/14 | 4,255 | 4,320 | 4,245 | 4,320 | +65 | +1.5% | 88,100 |
2022/01/13 | 4,255 | 4,270 | 4,220 | 4,255 | +10 | +0.2% | 62,200 |
2022/01/12 | 4,205 | 4,260 | 4,205 | 4,245 | +40 | +1% | 58,200 |
2022/01/11 | 4,195 | 4,230 | 4,180 | 4,205 | +50 | +1.2% | 55,100 |
2022/01/07 | 4,180 | 4,210 | 4,140 | 4,155 | -35 | -0.8% | 62,300 |
2022/01/06 | 4,190 | 4,240 | 4,190 | 4,190 | -10 | -0.2% | 45,100 |
2022/01/05 | 4,230 | 4,230 | 4,195 | 4,200 | -45 | -1.1% | 55,300 |
2022/01/04 | 4,220 | 4,255 | 4,210 | 4,245 | +35 | +0.8% | 55,600 |
2021/12/30 | 4,250 | 4,250 | 4,210 | 4,210 | -55 | -1.3% | 47,100 |
2021/12/29 | 4,240 | 4,295 | 4,240 | 4,265 | +45 | +1.1% | 55,200 |
2021/12/28 | 4,180 | 4,230 | 4,170 | 4,220 | +35 | +0.8% | 41,600 |
2021/12/27 | 4,200 | 4,200 | 4,170 | 4,185 | -30 | -0.7% | 26,800 |
2021/12/24 | 4,230 | 4,240 | 4,200 | 4,215 | ±0 | ±0% | 33,600 |
2021/12/23 | 4,265 | 4,275 | 4,205 | 4,215 | -15 | -0.4% | 38,600 |
2021/12/22 | 4,240 | 4,265 | 4,215 | 4,230 | -10 | -0.2% | 50,800 |
2021/12/21 | 4,230 | 4,280 | 4,230 | 4,240 | +15 | +0.4% | 60,300 |
2021/12/20 | 4,195 | 4,230 | 4,175 | 4,225 | +5 | +0.1% | 74,900 |
2021/12/17 | 4,215 | 4,245 | 4,195 | 4,220 | -10 | -0.2% | 107,700 |
2021/12/16 | 4,225 | 4,235 | 4,195 | 4,230 | +60 | +1.4% | 53,000 |
2021/12/15 | 4,145 | 4,200 | 4,145 | 4,170 | ±0 | ±0% | 42,800 |
2021/12/14 | 4,130 | 4,190 | 4,130 | 4,170 | +55 | +1.3% | 66,100 |
2021/12/13 | 4,175 | 4,175 | 4,110 | 4,115 | -20 | -0.5% | 51,100 |
2021/12/10 | 4,140 | 4,150 | 4,115 | 4,135 | -50 | -1.2% | 75,200 |
2021/12/09 | 4,260 | 4,260 | 4,165 | 4,185 | -40 | -0.9% | 54,300 |
2021/12/08 | 4,235 | 4,250 | 4,205 | 4,225 | -15 | -0.4% | 86,000 |
2021/12/07 | 4,195 | 4,240 | 4,150 | 4,240 | +85 | +2% | 93,300 |
2021/12/06 | 4,210 | 4,240 | 4,150 | 4,155 | -15 | -0.4% | 58,200 |
2021/12/03 | 4,085 | 4,175 | 4,085 | 4,170 | +85 | +2.1% | 76,200 |
2021/12/02 | 4,025 | 4,125 | 4,010 | 4,085 | +40 | +1% | 87,200 |
2021/12/01 | 4,030 | 4,065 | 4,010 | 4,045 | ±0 | ±0% | 92,500 |
2021/11/30 | 4,070 | 4,125 | 4,045 | 4,045 | -35 | -0.9% | 122,200 |
2021/11/29 | 4,095 | 4,120 | 4,080 | 4,080 | -60 | -1.4% | 87,300 |
2021/11/26 | 4,170 | 4,170 | 4,100 | 4,140 | -50 | -1.2% | 59,100 |
2021/11/25 | 4,190 | 4,205 | 4,175 | 4,190 | -5 | -0.1% | 33,700 |
2021/11/24 | 4,260 | 4,265 | 4,190 | 4,195 | -65 | -1.5% | 61,600 |
2021/11/22 | 4,225 | 4,270 | 4,225 | 4,260 | +5 | +0.1% | 56,900 |
2021/11/19 | 4,225 | 4,280 | 4,225 | 4,255 | +20 | +0.5% | 72,900 |
2021/11/18 | 4,250 | 4,270 | 4,230 | 4,235 | -20 | -0.5% | 72,700 |
2021/11/17 | 4,250 | 4,270 | 4,235 | 4,255 | -5 | -0.1% | 62,500 |
2021/11/16 | 4,265 | 4,295 | 4,255 | 4,260 | -40 | -0.9% | 70,300 |
2021/11/15 | 4,250 | 4,300 | 4,235 | 4,300 | +5 | +0.1% | 67,300 |
2021/11/12 | 4,265 | 4,315 | 4,265 | 4,295 | +25 | +0.6% | 52,800 |
2021/11/11 | 4,270 | 4,295 | 4,255 | 4,270 | -25 | -0.6% | 48,400 |
801~
850
件表示中 / 3692件
類似銘柄と比較する
現在ご覧いただいている「科研薬」と類似性の高い銘柄をピックアップ。投資家が注目しているデータで比較できるようになっています。銘柄選びの参考情報としてご活用ください。
銘柄名 | 最低購入代金 | 売上高 成長率 |
経常 増益率 |
配当 利回り |
PER | PBR | 直近のチャート | 特色 |
---|---|---|---|---|---|---|---|---|
科研薬 | 407,200円 | +30.5% | +111.0% | 4.67% | 11.48倍 | 1.00倍 |
|
旧理研グループの名門。導入の関節機能改善剤、自社創製の爪白癬症薬の2本柱。後発品も展開 |
日本新薬 | 373,500円 | +7.9% | +8.9% | 3.32% | 7.99倍 | 1.07倍 |
|
医家向け医薬品主体、自社創薬は泌尿器科、血液内科、難病・希少疾患に集中。機能食品も育成 |
サワイGHD | 203,300円 | +4.0% | +25.4% | 2.61% | 8.89倍 | 1.17倍 |
|
ジェネリック(後発)薬大手メーカー。21年春に沢井製薬が持株会社化。大型買収で米国本格展開 |
キッセイ薬 | 379,500円 | +14.5% | -2.3% | 2.37% | 13.88倍 | 0.74倍 |
|
医薬品中堅。泌尿器、腎・透析、未充足医療が重点領域。主軸特許切れ、新しい柱育成。海外は導出 |
サンバイオ | 229,900円 | - | - | 0.00% | - | 106.48倍 |
|
脳疾患向け再生細胞薬の開発・製造・販売目指すバイオベンチャー。米国で創業し日本に逆上陸 |
市場注目の銘柄
チャート関連のコラム